Company news

Dare Bioscience, Inc. news in 2021

Dare Bioscience, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis

December 6, 2021

Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update

November 9, 2021

Daré Bioscience to Host Third Quarter 2021 Financial Results and Company Update Conference Call and Webcast on November 10, 2021

November 2, 2021

Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1

September 26, 2021

Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy

September 22, 2021

Daré Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update

August 11, 2021

Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis

August 8, 2021

Daré Bioscience to Host Second Quarter 2021 Financial Results and Company Update Conference Call and Webcast on August 12, 2021

August 4, 2021

Daré Announces Collaborative Research Agreement (CRADA) for the Pivotal Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Contraceptive

July 11, 2021

Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1

June 27, 2021

Daré Bioscience Reports First Quarter 2021 Financial Results and Provides a Company Update

May 12, 2021

Daré Bioscience to Host First Quarter 2021 Financial Results and Company Update Conference Call and Webcast on May 13, 2021

May 5, 2021

Daré Bioscience Announces Ovaprene®, a Novel Investigational Hormone-Free Contraceptive, Poster Presentation at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists

April 26, 2021

Daré Bioscience Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists

April 25, 2021

Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors

April 18, 2021

Daré Bioscience Reports Full Year 2020 Financial Results and Provides a Company Update

March 29, 2021

Daré Bioscience Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

March 23, 2021

Calls in 2021

Decks in 2021